Instrument NameBristol-Myers Squibb CompanyInstrument Symbol(BMY-N)

Instrument ExchangeNYSE

Low valuations don't always guarantee gains are in the offing. You need a company firing on all cylinders, too.

Sometimes the stock market offers its own version of Black Friday deals.

Stocks that traded heavily or had substantial price changes on Monday: Microsoft, Palantir rise; Bristol-Myers, Kohl’s fall

A high-profile clinical failure by a rival is weighing on the drugmaker's shares today.

A survey of North American equities heading in both directions

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

Wall Street aims to close out a third consecutive winning week. Several retailers' stocks have popped in early Friday trading. Four long-duration call options have caught my attention. I’ve ranked them from best to worst.

It isn't exactly a growth stock, but it has a few features that could make you richer.

The stock isn't nearly as risky as its low valuation suggests.

High-yield stocks that trade at a value and come with a lower-than-average beta can help mitigate portfolio volatility and boost returns over time.

There's a lot more at stake than bragging rights.

Here's a look at two dividend value stocks with high yields that Wall Street recommends buying.

A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts.

There are very good reasons that stocks generally gain in value after a company receives orphan drug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock price of a company increased by 3.36% after the announcement of an orphan designation. The impact was...

There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock price of a company increased by 3.36%...

The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector

BMY earnings call for the period ending September 30, 2023.

You won't have to worry about paying a premium for either one of these stocks -- and they both pay a solid dividend.

There's more to the AI boom than Microsoft and ChatGPT.

Investors are loving LianBio's new deal with Bristol Myers Squibb.

The venerable pharmaceutical companies' shares have slumped this year.

The stock is down this year, but will its struggles fade into the rearview mirror?

Bristol Myers has been investing in growth, but will it be enough to get investors bullish on its struggling stock?

These two blue-chip stocks sport generous yields.

These two well-known drugmakers still have some growth fuel in their seemingly empty tanks.